Antiememicafungin is extended to infants under 4 months

Newborn Astaire recently announced that the U.S FDA has approved the application of mycamine (micafungin injection) as a new drug supplement for infants under 4 months to treat candidemia, acute disseminated candidiasis, candidal peritonitis and abscess without meningitis and / or ocular transmission Candidiasis in infants is associated with 20% of mortality and significant incidence rate and mortality In 2005, mycamine was approved for the treatment of adult candidiasis; in 2013, mycamine was approved for children aged 4 months and over With this approval, mycamine is the first antifungal drug approved in the United States specifically for the treatment of invasive candidiasis in infants under 4 months of age Although rare, invasive candidiasis has a unique pathogenesis that has been confirmed in newborns, which is different from that in older children and adults It is characterized by a higher incidence of organ involvement, especially in the central nervous system The safety of mycamine in infants has been evaluated in nine clinical trials, with 164 infants under 4 months receiving different doses of mycamine In terms of medication, mycamine was approved as 4mg / kg once a day in newborns and infants under 4 months old Micafungin (micafungin) is the active component of mycamine, which is a new echinocandin antifungal drug obtained by modifying and synthesizing the natural product of coleophomaempetri It can inhibit the enzymes necessary for the synthesis of fungal cell wall, and has a bactericidal (lethal) effect on Candida The drug can be used in combination with a variety of other drugs, including the HIV protease inhibitor ritonavir and the inhibitor cyclosporine and tacrolimus Mycamine is suitable for children and adults: for children and adults over 4 months, for the treatment of candidemia, acute disseminated candidiasis, candidal peritonitis and abscess; for children under 4 months, for the treatment of non meningitis and / or eye transmitted candidemia, acute disseminated candidiasis, candidal peritonitis and abscess; It is used for children and adults over 4 months to treat esophageal candidiasis, and for children and adults over 4 months to receive hematopoietic stem cell transplantation to prevent candidiasis Mycamine's most common adverse reactions in all adult and pediatric clinics include diarrhea, nausea, vomiting, abdominal pain, fever, thrombocytopenia, neutropenia, and headache The incidence of adverse reactions, septicemia, acidosis, anemia, decreased oxygen saturation and hypokalemia was more than 15% in children under 4 months Mycamine is prohibited in individuals who are allergic to micafungin, any component of mycamine or other echinocandin Adorable adorable